Chemotherapy-nave patients with stage III , stage IV , or recurrent NSCLC age @ years with a performance status of @ or @ who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel @ mg/m ( @ ) on day @ , every @ weeks , or docetaxel @ mg/m ( @ ) plus cisplatin @ mg/m ( @ ) on days @ , @ , and @ , every @ weeks .